SkyePharma Inc. announced today that the company has changed its name to Pacira Pharmaceuticals, Inc. The name change reflects Pacira’s transformation from a former business unit of SkyePharma PLC to an independent, private company with existing commercial products, a strong product in clinical
EKR Therapeutics, Inc., a specialty pharmaceutical company focused on acquiring, developing, and commercializing proprietary products to enhance patient quality-of-life in the acute care setting, today announced it has acquired exclusive marketing and distribution rights to DepoDur ® (morphine
Flynn Pharma Limited, a specialty pharmaceutical company focused on acquiring and commercializing proprietary products in secondary healthcare and related markets, today announced it has acquired exclusive marketing and distribution rights to DepoDur ® (morphine sulphate extended release liposome
Pacira Pharmaceuticals, Inc. today announced that Orphan Australia Pty Ltd, an Australian owned pharmaceutical company dedicated to providing novel, highly specialized pharmaceuticals, has been granted registration approval by the Therapeutic Goods Administration for DepoDur ® in Australia.
Pacira Pharmaceuticals, Inc., a leader in sustained release injectable technologies, today announced that David M. Stack has been selected as President, Chief Executive Office, and member of the Board of Directors. Mr. Stack is currently the CEO and founding partner of Stack Pharmaceuticals, Inc.,
Pacira Pharmaceuticals, Inc. today announced a collaboration with Amylin Pharmaceuticals, Inc. for the development of sustained release injectable products based on the DepoFoam ® technology platform from Pacira. The companies will work together to enhance the dosing profile for compounds within
Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, today announced the appointment of a new Board member and the addition of a key senior executive to the company’s management team. Gary Pace, Ph.D, joins the Board of Directors as a seasoned biopharmaceutical executive
Parsippany, NJ, August 6 2008 - Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, today announced the addition of a key senior executive to the company's management team. James S. Scibetta, joins Pacira as the Chief Financial Officer. Mr.
Parsippany, NJ, October 2, 2008 – Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, today announced the addition of a key senior executive to the company’s management team. David St. Peter, M.D. joins Pacira as Vice President of Medical Education and Scientific Affairs.
New Sustained-Release Analgesic Significantly Reduces Postop Pain, Opioid Use, and Reduces Opioid Related Adverse Events Compared to Gold Standard Pain Medication Parsippany, NJ, Dec. 6, 2008 - A Phase II dose escalation study of a single intraoperative administration of EXPAREL ™ (DepoBupivacaine)
